1. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells
- Author
-
Bellone, M., Iezzi, G., Martin-Fontecha, A., Rivolta, L., Manfredi, A. A., Protti, M. P., Freschi, M., Paolo Dellabona, Casorati, G., Rugarli, C., Bellone, M, Iezzi, G, Martinfontecha, A, Rivolta, L, Manfredi, ANGELO ANDREA M. A., Protti, Mp, Freschi, M, Dellabona, P, Casorati, G, and Rugarli, C.
- Subjects
Graft Rejection ,Vaccines, Synthetic ,Immunology ,Melanoma, Experimental ,Antigen-Presenting Cells ,Cancer Vaccines ,Killer Cells, Natural ,Mice, Inbred C57BL ,Mice ,Antigens, Neoplasm ,B7-1 Antigen ,Animals ,Immunology and Allergy ,Female ,T-Lymphocytes, Cytotoxic - Abstract
Naturally processed peptides, obtained by acid extraction of tumor cells, contain Ags able to activate specific CTL in vitro. We recently reported that the nonprofessional APC, RMA-S, expressing the B7.1 molecule (RMA-S/B7), pulsed with naturally processed peptides from the nonimmunogenic B16F1 melanoma (B16F1a.e.) primed syngenic CD8+ T cells against the tumor in vitro. Here, we show the rejection of B16F1 melanoma by C57BL/6 mice after immunization with RMA-S/B7 cells pulsed with B16F1a.e. This response is critically dependent on both CD4+ and CD8+ cells, but not on NK cells. However, only CD8+ T cells exert anti-B16F1 cytolitic activity in vitro. Moreover, RMA-S/B7 cells pulsed with B16F1a.e. can be used to prevent the growth of 24-h preestablished melanomas. These results may have important implications for the clinical use of natural peptide fractions of tumor cells as therapeutic cancer vaccines.
- Published
- 1997